Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults

JAMA Neurology

Volumn 72, Issue 5, 2015, Pages 546-553

  Nation, Daniel A ^a   Edmonds, Emily C ^b   Bangen, Katherine J ^b,c   Delano Wood, Lisa ^c   Scanlon, Blake K ^d   Han, S Duke ^e,f   Edland, Steven D ^g   Salmon, David P ^d,g   Galasko, Douglas R ^c,g   Bondi, Mark W ^b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^f RUSH UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; AMYLOIDOSIS; ARTICLE; BODY MASS; CEREBRAL AMYLOIDOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MALE; MEAN ARTERIAL PRESSURE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULSE PRESSURE; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; AGING; BLOOD PRESSURE; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR AMYLOIDOSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; BIOMARKERS; BLOOD PRESSURE; CEREBRAL AMYLOID ANGIOPATHY; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84981263614     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.4477     Document Type: Article

References (33)

1. Knopman DS, Roberts R. Vascular risk factors: imaging and neuropathologic correlates. J Alzheimers Dis. 2010;20(3):699-709.
2. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? an evidence-based review. Alzheimers Res Ther. 2012;4(1):1.
3. Langbaum JB, Chen K, Launer LJ, et al Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012;33(4):827 e811-829.
4. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD Sr, Diaz-Arrastia R, Park DC. Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 2013;70(5):600-606.
5. Nation DA, Edland SD, Bondi MW, et al. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology. 2013;81 (23):2024-2027.
6. Hughes TM, Kuller LH, Barinas-Mitchell EJ, et al. Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults. Neurology. 2013;81(19):1711-1718.
7. Waldstein SR, Rice SC, Thayer JF, Najjar SS, Scuteri A, Zonderman AB. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51(1):99-104.
8. Peters R, Beckett N, Fagard R, et al. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial. HYVET.JHypertens. 2013;31(9):1868-1875.
9. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200-208.
10. Yarchoan M, Xie SX, Kling MA, et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(pt 12):3749-3756.
11. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 2013;136(pt 9):2697-2706.
12. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778-1783.
13. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology.2010; 74(3):201-209.
14. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. the Framingham Study. Stroke. 1994;25(1):40-43.
15. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
16. de Simone G, Roman MJ, Alderman MH, Galderisi M, de Divitiis O, Devereux RB. Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension. 2005;45(4):575-579.
17. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
18. Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 2013;80(6):1347-1358.
19. Drachman DA. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement. 2014;10(3):372-380.
20. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.Ann Neurol. 2012;71(6):765-775.
21. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol. 2013;73(4):472-480.
22. Knopman DS. β-Amyloidosis and neurodegeneration in Alzheimer disease: who's on first? Neurology. 2014;82(20):1756-1757.
23. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol.2013; 12(2):207-216.
24. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.Nat Rev Neurosci. 2011;12(12):723-738.
25. Nation DA, Wierenga CE, Clark LR, et al. Cortical and subcortical cerebrovascular resistance index in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2013;36(4):689-698.
26. Clark L, Nation DA, Wierenga CE, et al. Elevated cerebrovascular resistance index is associated with cognitive dysfunction in the very-old. Alzheimers Res Ther. 2015;7(3):1-9.
27. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy.Acta Neuropathol. 2009;118(1):87-102.
28. Bendlin BB, Carlsson CM, Johnson SC, et al. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One. 2012;7(6):e37720.
29. Mitchell GF, van Buchem MA, Sigurdsson S, et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility. Reykjavik study. Brain. 2011;134(pt 11):3398-3407.
30. Waldstein SR, Wendell CR, Lefkowitz DM, et al. Interactive relations of blood pressure and age to subclinical cerebrovascular disease. J Hypertens. 2012;30(12):2352-2356.
31. Franklin SS, Chow VH, Mori AD, Wong ND. The significance of low DBP in US adults with isolated systolic hypertension.JHypertens. 2011;29(6):1101-1108.
32. Skoog I, Lernfelt B, Landahl S, et al. 15-Year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-1145.
33. Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer's disease begin? Curr Opin Neurol. 2012;25(6):708-714.